Goal 3: Advance Translational Research

Substituting scientific-medical insight before profit in drug development

Since the Pure Food and Drug Act of 1906 and the rise of the FDA, the US federal government has directly inserted itself into medical research, primarily from a business perspective. The Orphan Drug Act of 1983 monetarily incentivized the process for rare diseases, but for ultra-rare diseases of < 1,000 patients, it does not work. Successful drugs for rare diseases have enormous price tags to compensate their development expenses and reward investors, which dilutes the amount of healthcare funds available for all citizens. The Challenge is to provide an alternative drug testing process for the non-profit that takes advantage of the intellect and dedication of altruistic medical researchers who seek to find cures and not monetary profit.

Tags (Keywords associated with the idea)


6 net votes
11 up votes
5 down votes
Idea No. 696